Cyprus Mail

Drug shown to delay spread of prostrate cancer

Prostate cancer is the leading cancer affecting men

German drugmaker Bayer and Finland’s Orion said on Wednesday a study showed a prostate cancer drug they are jointly developing can delay the spread of the disease to other parts of the body.

A study on men with non-metastatic prostate cancer that could not be helped with hormonal therapy met the primary goal of showing oral drug darolutamide can delay the spread of metastases, the companies said in a statement.

Shares in Orion, which sold certain rights to the drug in a collaboration deal with Bayer in 2014, were up 7.5 percent at 0740 GMT, while Bayer’s shares were down 0.8 percent.

Full details of the trials will be presented at a medical conference, Bayer said.

Bayer added it would now speak to health authorities about a possible request for marketing approval of darolutamide, a compound that was granted “fast track” designation by the U.S. Food and Drug Administration in the prostate cancer setting, potentially speeding the approval process.

Bayer shares slumped on Tuesday after a U.S. judge affirmed a verdict against its Monsanto unit that found glyphosate-based weedkillers responsible for a man’s terminal cancer.

Related Posts

Return of the flu: EU faces threat of prolonged ‘twindemic’

Reuters News Service

GSK rejects 50-billion-pound Unilever offer for consumer assets

Reuters News Service

Bedridden patients entitled to 12 house calls a year from GP

Anna Savva

Future viability of Gesy discussed at broad meeting

Antigoni Pitta

Patients’ group concerned about ongoing instability in Gesy 

Jonathan Shkurko

EU drug regulator expresses doubt on need for fourth jab

Reuters News Service